Botulinum toxin type A effectively manages sialorrhea in pediatric and adult neurological disordersBotulinum toxin helps manage drooling in neurological conditions

BackgroundAspiration pneumonia (AP), a serious condition resulting from the inhalation of foreign materials into the lungs, is a significant concern for patients with compromised swallowing mechanisms, especially those with neurological disorders. Sialorrhea (hypersalivation) exacerbates the risk of aspiration, and botulinum neurotoxin type A (BoNT-A) has been identified as a potential treatment to manage sialorrhea. However, the direct impact of BoNT-A on reducing AP risk remains inadequately explored, particularly in adult populations. BoNT-A works by inhibiting the release of acetylcholine at the neuromuscular junction, thereby reducing salivary gland stimulation and saliva production.ObjectiveThis review aims to evaluate the current state of research on the use of BoNT-A for managing sialorrhea and its potential to reduce AP risk, with a specific focus on the adult population.MethodsA comprehensive review of existing literature was conducted, focusing on the efficacy of BoNT-A in treating sialorrhea in both pediatric and adult populations. Studies were assessed for their findings on the impact of BoNT-A on drooling and related complications, including the risk of AP. Meta-analyses and individual studies were reviewed to summarize the current knowledge and identify research gaps.ResultsIn pediatric patients, BoNT-A has been shown to effectively reduce sialorrhea, with several studies and meta-analyses demonstrating its efficacy in managing drooling associated with neurological conditions such as cerebral palsy. However, evidence linking BoNT-A directly to reduced AP risk is limited. In adults, while BoNT-A has been beneficial in managing sialorrhea associated with conditions such as Parkinson's disease and brain injuries, studies specifically exploring its impact on AP risk are lacking.ConclusionCurrent evidence supports the efficacy of BoNT-A in managing neurological sialorrhea across both adult and pediatric populations. However, a critical gap exists in studies directly investigation whether BoNT-A reduces AP risk in adults with neurological disease.